ATE400550T1 - Sulfone mit modulierender wirkung auf die gamma- sekretase - Google Patents
Sulfone mit modulierender wirkung auf die gamma- sekretaseInfo
- Publication number
- ATE400550T1 ATE400550T1 AT01960923T AT01960923T ATE400550T1 AT E400550 T1 ATE400550 T1 AT E400550T1 AT 01960923 T AT01960923 T AT 01960923T AT 01960923 T AT01960923 T AT 01960923T AT E400550 T1 ATE400550 T1 AT E400550T1
- Authority
- AT
- Austria
- Prior art keywords
- sulfones
- gamma secretase
- modulating effect
- secretase
- gamma
- Prior art date
Links
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 title abstract 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 title abstract 2
- 150000003457 sulfones Chemical class 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000001174 sulfone group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Control Of El Displays (AREA)
- Radio Relay Systems (AREA)
- Control Of Indicators Other Than Cathode Ray Tubes (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0108592.7A GB0108592D0 (en) | 2001-04-05 | 2001-04-05 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE400550T1 true ATE400550T1 (de) | 2008-07-15 |
Family
ID=9912330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01960923T ATE400550T1 (de) | 2001-04-05 | 2001-08-21 | Sulfone mit modulierender wirkung auf die gamma- sekretase |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7411004B2 (de) |
| EP (1) | EP1379496B1 (de) |
| JP (1) | JP2004531517A (de) |
| AT (1) | ATE400550T1 (de) |
| AU (1) | AU2001282313B2 (de) |
| CA (1) | CA2442885C (de) |
| DE (1) | DE60134788D1 (de) |
| GB (1) | GB0108592D0 (de) |
| WO (1) | WO2002081433A1 (de) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0108591D0 (en) * | 2001-04-05 | 2001-05-23 | Merck Sharp & Dohme | Therapeutic agents |
| GB0120347D0 (en) | 2001-08-21 | 2001-10-17 | Merck Sharp & Dohme | Therapeutic agents |
| AU2002367147A1 (en) * | 2001-12-27 | 2003-07-15 | Daiichi Pharmaceutical Co., Ltd. | Beta-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS |
| DE10201392A1 (de) * | 2002-01-16 | 2003-07-31 | Bayer Ag | Phenylsulfoxide und-sulfone |
| GB0223039D0 (en) | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
| DE10254875A1 (de) * | 2002-11-25 | 2004-06-03 | Bayer Healthcare Ag | Phenylsulfoxid und -sulfon-Derivate |
| GB0308318D0 (en) | 2003-04-10 | 2003-05-14 | Merck Sharp & Dohme | Therapeutic agents |
| WO2004101538A1 (en) * | 2003-05-16 | 2004-11-25 | Merck Sharp & Dohme Limited | Cyclohexyl sulphones as gamma-secretase inhibitors |
| PL379466A1 (pl) | 2003-06-30 | 2006-09-18 | Daiichi Sankyo Company , Limited | Heterocykliczne pochodne metylosulfonu |
| ZA200509613B (en) * | 2003-06-30 | 2007-05-30 | Daiichi Seiyaku Co | Heterocyclic methyl sulfone derivative |
| AR047666A1 (es) * | 2004-02-20 | 2006-02-01 | Merck Sharp & Dohme | Sintesis estereoselectiva del acido ciclohexanopropanoico 4,4-disubstituido |
| AU2006234441B2 (en) | 2005-04-08 | 2011-07-07 | Daiichi Sankyo Company, Limited | Pyridylmethylsulfone derivative |
| EP1888050B1 (de) | 2005-05-17 | 2012-03-21 | Merck Sharp & Dohme Ltd. | Cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropansäure zur Behandlug von Krebs |
| JP2010518064A (ja) | 2007-02-12 | 2010-05-27 | メルク・シャープ・エンド・ドーム・コーポレイション | Ａｄおよび関連状態の治療のためのピペラジン誘導体 |
| TW200920362A (en) | 2007-09-11 | 2009-05-16 | Daiichi Sankyo Co Ltd | Alkylsulfone derivatives |
| BRPI0821090B8 (pt) | 2007-12-21 | 2021-05-25 | Ligand Pharm Inc | moduladores seletivos de receptores de androgênio (sarms) e uso do mesmo |
| EP2291181B9 (de) | 2008-04-18 | 2013-09-11 | University College Dublin National University Of Ireland, Dublin | Captodiamine zur Behandlung von depressionartigen Symptomen |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| AU2010307198B9 (en) | 2009-10-14 | 2014-02-13 | Merck Sharp & Dohme Corp. | Substituted piperidines that increase p53 activity and the uses thereof |
| EP2584903B1 (de) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Neue heterozyklische verbindungen als erk-hemmer |
| JP6043285B2 (ja) | 2010-08-02 | 2016-12-14 | サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| LT2606134T (lt) | 2010-08-17 | 2019-07-25 | Sirna Therapeutics, Inc. | Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina) |
| US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| EP2615916B1 (de) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Kondensierte pyrazolderivate als neue erk-hemmer |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| EP2654748B1 (de) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazolderivate als erk-hemmer |
| EP2770987B1 (de) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Neue verbindungen als erk-hemmer |
| EP3453762B1 (de) | 2012-05-02 | 2021-04-21 | Sirna Therapeutics, Inc. | Sina-zusammensetzungen |
| EP2900241B1 (de) | 2012-09-28 | 2018-08-08 | Merck Sharp & Dohme Corp. | Neuartige verbindungen als erk-hemmer |
| AU2013352568B2 (en) | 2012-11-28 | 2019-09-19 | Merck Sharp & Dohme Llc | Compositions and methods for treating cancer |
| ES2707305T3 (es) | 2012-12-20 | 2019-04-03 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de HDM2 |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| EP3041938A1 (de) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Kreisförmige polynukleotide |
| EP3094323A4 (de) | 2014-01-17 | 2017-10-11 | Ligand Pharmaceuticals Incorporated | Verfahren und zusammensetzungen zur modulierung von hormonspiegeln |
| WO2018071283A1 (en) | 2016-10-12 | 2018-04-19 | Merck Sharp & Dohme Corp. | Kdm5 inhibitors |
| US11098059B2 (en) | 2017-11-08 | 2021-08-24 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US11993602B2 (en) | 2018-08-07 | 2024-05-28 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| US12552826B2 (en) | 2018-08-07 | 2026-02-17 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| US12173026B2 (en) | 2018-08-07 | 2024-12-24 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| EP3956309A4 (de) | 2019-04-19 | 2023-06-07 | Ligand Pharmaceuticals Inc. | Kristalline formen und verfahren zur herstellung kristalliner formen einer verbindung |
| WO2021126732A1 (en) | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| CA3160153A1 (en) | 2019-12-17 | 2021-06-24 | Michelle Machacek | Prmt5 inhibitors |
| EP4076459A4 (de) | 2019-12-17 | 2023-12-20 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| US12441730B2 (en) | 2019-12-17 | 2025-10-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| JP7595854B2 (ja) * | 2020-05-25 | 2024-12-09 | 地方独立行政法人大阪産業技術研究所 | ［６，６］メタノフラーレン誘導体の製造方法 |
| AU2023336062A1 (en) | 2022-09-02 | 2025-03-13 | Merck Sharp & Dohme Llc | Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof |
| KR20250079227A (ko) | 2022-10-25 | 2025-06-04 | 머크 샤프 앤드 돔 엘엘씨 | 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도 |
| AU2023397331A1 (en) | 2022-12-14 | 2025-06-26 | Merck Sharp & Dohme Llc | Auristatin linker-payloads, pharmaceutical compositions, and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3016403A (en) * | 1955-07-29 | 1962-01-09 | Searle & Co | 1-aryl-3-hydroxypropyl sulfones and processes |
| JPS537691A (en) * | 1976-07-09 | 1978-01-24 | Yoshitomi Pharmaceut Ind Ltd | Piperazines |
| DE2735314A1 (de) * | 1977-08-05 | 1979-02-22 | Basf Ag | Alpha-azolylsulfide und deren derivate |
| US4675316A (en) * | 1978-03-10 | 1987-06-23 | Rohm And Haas Company | Substituted azoylmethylarylsulfides and derivatives and pesticidal use thereof |
| DE2821829A1 (de) * | 1978-05-19 | 1979-11-22 | Basf Ag | Mittel zur regulierung des pflanzenwachstums |
| JPS5626847A (en) | 1979-08-13 | 1981-03-16 | Sagami Chem Res Center | Preparation of substituted salicylic acid derivative |
| JPS5716840A (en) * | 1980-07-03 | 1982-01-28 | Sagami Chem Res Center | Phneylacetic acid derivative |
| US4379921A (en) * | 1980-08-21 | 1983-04-12 | Sumitomo Chemical Company, Limited | Production of triazolylvinyl ketones |
| FR2593178B1 (fr) * | 1986-01-20 | 1988-04-29 | Esteve Labor Dr | Derives de 2-benzimidazolylalkylthio (ou sulfinyle ou sulfonyle) leur preparation et leur application en tant que medicaments. |
| JPS62181260A (ja) * | 1986-02-06 | 1987-08-08 | Nippon Kayaku Co Ltd | ピリジン誘導体およびそれを有効成分とする農園芸用殺菌剤 |
| JP3582070B2 (ja) * | 1994-08-11 | 2004-10-27 | 日本曹達株式会社 | フェニルエタン誘導体及びそれを用いた感熱記録材料 |
| IL128079A0 (en) * | 1996-07-22 | 1999-11-30 | Monsanto Co | Thiol sulfone metalloprotease inhibitors |
| US5703129A (en) * | 1996-09-30 | 1997-12-30 | Bristol-Myers Squibb Company | 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production |
| MXPA01008606A (es) | 1999-02-26 | 2003-05-05 | Merck & Co Inc | Compuestos de sulfonamida novedosos y uso de los mismos. |
| SE9901901D0 (sv) * | 1999-05-26 | 1999-05-26 | Astra Ab | Compounds |
| AU2002367147A1 (en) | 2001-12-27 | 2003-07-15 | Daiichi Pharmaceutical Co., Ltd. | Beta-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS |
| DE10201392A1 (de) | 2002-01-16 | 2003-07-31 | Bayer Ag | Phenylsulfoxide und-sulfone |
-
2001
- 2001-04-05 GB GBGB0108592.7A patent/GB0108592D0/en not_active Ceased
- 2001-08-21 DE DE60134788T patent/DE60134788D1/de not_active Expired - Lifetime
- 2001-08-21 JP JP2002579421A patent/JP2004531517A/ja active Pending
- 2001-08-21 AU AU2001282313A patent/AU2001282313B2/en not_active Ceased
- 2001-08-21 WO PCT/GB2001/003778 patent/WO2002081433A1/en not_active Ceased
- 2001-08-21 EP EP01960923A patent/EP1379496B1/de not_active Expired - Lifetime
- 2001-08-21 US US10/473,767 patent/US7411004B2/en not_active Expired - Fee Related
- 2001-08-21 AT AT01960923T patent/ATE400550T1/de not_active IP Right Cessation
- 2001-08-21 CA CA2442885A patent/CA2442885C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2442885A1 (en) | 2002-10-17 |
| AU2001282313B2 (en) | 2008-01-10 |
| JP2004531517A (ja) | 2004-10-14 |
| EP1379496A1 (de) | 2004-01-14 |
| US20040082617A1 (en) | 2004-04-29 |
| WO2002081433A1 (en) | 2002-10-17 |
| GB0108592D0 (en) | 2001-05-23 |
| CA2442885C (en) | 2010-06-29 |
| DE60134788D1 (de) | 2008-08-21 |
| US7411004B2 (en) | 2008-08-12 |
| EP1379496B1 (de) | 2008-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE400550T1 (de) | Sulfone mit modulierender wirkung auf die gamma- sekretase | |
| ATE498608T1 (de) | Sulfone, die die aktivität von gamma-secretase modulieren | |
| DE69434313D1 (de) | Superoxiddismutase memetika | |
| EA200400331A1 (ru) | Новые циклогексилсульфоны | |
| EE9900469A (et) | Sulfoonamiidid endoteliini vahendatud haiguste raviks | |
| PT847757E (pt) | Medicamento que compreende o gene de hgf | |
| BR0210205A (pt) | Antiinfecciosos | |
| DE60030429D1 (de) | Neuronale, die exozytose hemmende peptide und diese enthaltende kosmetische und pharmazeutische zusammensetzungen | |
| DE50112902D1 (de) | Hautreinigungsmittel | |
| BR9712491A (pt) | Composições cosméticas | |
| BR9913831A (pt) | Processo para tratamento de arteriosclerose empregando um inibidor de ap2 e combinação | |
| DK1071422T3 (da) | Kombinationer af riluzol og levodopa til behandling af parkinsons sygdom | |
| BR0317271A (pt) | Concentrado de suspensão em óleo | |
| BR0016178B1 (pt) | cabeÇal aplicador para aparelhos de estÉtica e eletromedicina. | |
| BR9901680A (pt) | Mecanismo de articulação, processos para montar e desmontar o mesmo, e, aparelho portátil. | |
| PT950354E (pt) | Composicoes fungicidas de ditiocarbamato | |
| ES2177024T3 (es) | Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer. | |
| BR0108405A (pt) | Agente de ativação de célula | |
| FI955429L (fi) | 1-aryylisykloalkyylisulfideja, sulfoksideja ja sulfoneja depression, tuskatilojen ja Parkinsonin taudin hoitamiseksi | |
| ES2065307T3 (es) | Producto y procedimiento para el moldeado permanente del cabello. | |
| EP0968707A3 (de) | Gegen Akne und entzündete Comedonen wirksame Zubereitungen enthaltend Serin-Proteasen und ein oder mehrere Calciumsalze | |
| WO2002096352A3 (en) | Long wearing emulsion composition for making up eyes and skin | |
| ID20165A (id) | Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis | |
| DK1235573T3 (da) | Kombination af riluzol og gabapentin og anvendelse deraf som medikament ved behandling af motorneuronsygdomme | |
| BR9909868A (pt) | Ascorbato de paroxetina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |